BRISTOL MYERS SQUIBB CO Logo

BRISTOL MYERS SQUIBB CO

Develops innovative medicines for oncology, immunology, and cardiovascular diseases.

BMY | US

Overview

Corporate Details

ISIN(s):
US1101222073 (+1 more)
LEI:
Country:
United States of America
Address:
ROUTE 206 AND PROVINCE LINE ROAD, 8543 PRINCETON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines to help patients prevail over serious diseases. The company's primary focus is on therapeutic areas with significant unmet medical needs, including oncology, hematology, immunology, and cardiovascular disease. Its operations encompass the full lifecycle of drug development, from scientific research and clinical trials to manufacturing, marketing, and distribution of its products worldwide. The company is committed to transforming patients' lives through scientific innovation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 17:06
Regulatory News Service
FORM 8-K
English 1.6 MB
2025-11-07 17:11
Prospectus
424B5
English 673.2 KB
2025-11-05 22:50
Regulatory News Service
FWP
English 17.4 KB
2025-11-04 23:19
Director's Dealing
FORM 4
English 7.4 KB
2025-11-04 23:18
Director's Dealing
FORM 4
English 8.2 KB
2025-11-04 23:15
Director's Dealing
FORM 4
English 7.5 KB
2025-11-04 23:13
Director's Dealing
FORM 4
English 7.7 KB
2025-11-03 12:09
Regulatory News Service
CURRENT REPORT
English 738.5 KB
2025-11-03 12:02
Prospectus
424B2
English 609.2 KB
2025-10-31 14:48
Major Shareholding Notification
English 8.6 KB
2025-10-30 17:04
Quarterly Report
10-Q
English 2.3 MB
2025-10-30 12:09
Regulatory News Service
8-K
English 2.9 MB
2025-10-06 23:22
Director's Dealing
FORM 4
English 7.4 KB
2025-10-03 00:20
Director's Dealing
FORM 4
English 7.4 KB
2025-10-03 00:18
Director's Dealing
FORM 4
English 7.3 KB

Automate Your Workflow. Get a real-time feed of all BRISTOL MYERS SQUIBB CO filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BRISTOL MYERS SQUIBB CO

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BRISTOL MYERS SQUIBB CO via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America
SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America
SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America
SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea
298060
scPharmaceuticals Inc. Logo
Commercializes subcutaneous drug-device therapies for at-home cardiorenal care.
United States of America
SCPH
SCYNEXIS INC Logo
Developing novel anti-fungal therapies for difficult-to-treat, drug-resistant infections.
United States of America
SCYX
Seach Medical Group Ltd. Logo
Researches, cultivates, and produces certified medical cannabis oils and flowers for global markets.
Israel
SEMG
SEEGENE, INC. Logo
Develops multiplex qPCR diagnostic assays and automated systems for labs and healthcare worldwide.
South Korea
096530
SEIKAGAKU CORPORATION Logo
A research pharma company using glycoscience to develop drugs for orthopedic & ophthalmic diseases.
Japan
4548
SELLAS Life Sciences Group, Inc. Logo
Late-stage biopharma developing novel immunotherapies for a broad range of cancers.
United States of America
SLS

Talk to a Data Expert

Have a question? We'll get back to you promptly.